Beam Therapeutics (BEAM) Soars %: Is Further Upside Left in the Stock? Zacks Jul 26 ET. Load More. Compared to the opening price on Wednesday 09/11/ on BTT of $, this is a gain of %. Beam Therapeutics Inc Registered Shs's market capitalization is. Get the latest Beam Therapeutics Inc. (BEAM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Beam Therapeutics Inc. ; Next Fiscal Year Estimate, ; Median PE on Next FY Estimate, N/A ; High, $ ; Median, $ ; Low, $ Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology.
Beam Therapeutics NasdaqGS:BEAM Stock Report ; Last Price. US$ ; Market Cap. US$b ; 7D. % ; 1Y. % ; Updated. 03 Sep, Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed. Beam Therapeutics Inc BEAM:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date02/27/24 · 52 Week Low. The Fund Sentiment Score (fka Ownership Accumulation Score) finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-. See BEAM stock price and Buy/Sell Beam Therapeutics. Discuss news and analysts' price predictions with the investor community. Start investingTrade Beam. Beam Therapeutics Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Press Releases · August 6, Beam Therapeutics Reports Pipeline Updates and Second Quarter Financial Results · July 15, Beam Therapeutics Announces. BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of Why Is Conn's (CONN) Stock Down 36% Today? CRISPR Therapeutics Nears Week Low. Time to Buy? You've Been Warned! 3 Gene Editing Stocks to Buy Now or. Beam Therapeutics News ; Beam Therapeutics price target lowered to $31 from $33 at Barclays · Beam Therapeutics price target lowered to $31 from $33 at Barclays. About Beam Therapeutics Inc Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision.
View the latest Beam Therapeutics Inc. (BEAM) stock price, news, historical charts, analyst ratings and financial information from WSJ. Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates. Beam Therapeutics (BEAM) delivered earnings and revenue surprises of % and %. In the current month, BEAM has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is $ On average, Wall Street analysts predict that Beam Therapeutics's share price could reach $ by Aug 22, The average Beam Therapeutics stock price. Discover real-time Beam Therapeutics Inc. Common Stock (BEAM) stock prices, quotes, historical data, news, and Insights for informed trading and investment. Latest news: Beam Therapeutics Inc. · Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue · Beam Therapeutics Inc. · Beam Therapeutics Shares. Beam Therapeutics Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - The current price of BEAM is USD — it has increased by % in the past 24 hours. Watch Beam Therapeutics Inc. stock price performance more closely on. “This year has the potential to be transformative for Beam as we work to advance multiple base editing programs in the clinic, anchoring key high-value.
Data delayed at least 15 minutes, as of Sep 11 BST. Use our equities screener to discover other potential opportunities. Find Similar Stocks. Pfizer announces deal worth up to $ billion with Beam; Beam's stock is up % Shares of Pfizer Inc. gained % in premarket trading on Monday after the. Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies. What is the forecast, or price target, for Beam Therapeutics (BEAM) stock? A. Beam Therapeutics has a consensus price target of $ Q. What is the. Beam Therapeutics Inc News & Analysis ; Beam Therapeutics Inc receives Investment Bank Analyst Rating Update · Aug 07, ; Beam earnings beat by $, revenue.
Syncom Formulations Share Analysis, Syncom Formulations Share News, Penny Pharma Share -
Based on short-term price targets offered by 12 analysts, the average price target for Beam Therapeutics Inc. comes to $ The forecasts range from a low of. Track Beam Therapeutics Inc (BEAM) Stock Price, Quote, latest community messages, chart, news and other stock related information. From what 0 stock analysts predict, the share price for Beam Therapeutics Inc (BEAM) might increase by % in the next year. This is based on a month.